Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis

NCT02589496 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
80
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Samsung Medical Center